Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates

Group 1 - Rigel Pharmaceuticals reported quarterly earnings of $0.63 per share, significantly exceeding the Zacks Consensus Estimate of $0.14 per share, and compared to a loss of $0.50 per share a year ago, representing an earnings surprise of 350% [1] - The company achieved revenues of $53.33 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 22.07%, and up from $29.53 million in the same quarter last year [2] - Rigel has consistently outperformed consensus EPS and revenue estimates over the last four quarters, indicating strong operational performance [2] Group 2 - The stock has increased approximately 13.6% since the beginning of the year, contrasting with a -3.9% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.31 on revenues of $48.14 million, and for the current fiscal year, it is $1.19 on revenues of $199.1 million [7] - The Medical - Drugs industry, to which Rigel belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook for the sector [8]